Mutational analysis of the IDUA gene was performed in a cohort of 102 European patients with mucopolysaccharidosis type I. A total of 54 distinct mutant IDUA alleles were identified, 34 of which were novel including 12 missense mutations, 2 nonsense mutations, 12 splicing mutations, 5 micro-deletions, 1 micro-duplication 1 translational initiation site mutation, and 1 'no-stop' change (p.X654RextX62). Evidence for the pathological significance of all novel mutations identified was sought by means of a range of methodological approaches, including the assessment of evolutionary conservation, RT-PCR/in vitro splicing analysis, MutPred analysis and visual inspection of the 3D-model of the IDUA protein. Taken together, these data not only demonstrate the remarkable mutational heterogeneity characterizing type 1 mucopolysaccharidosis but also illustrate our increasing ability to make deductions pertaining to the genotype-phenotype relationship in disorders manifesting a high degree of allelic heterogeneity.
is a rare autosomal recessive disorder resulting from deficiency of the lysosomal enzyme α-L-iduronidase (IDUA; E.C. 3.2.1.76) which is involved in the degradation of the glycosaminoglycans (GAGs), namely heparan sulfate and dermatan sulfate. IDUA deficiency leads to the intralysosomal accumulation of undegraded GAG substrates and this coincides with the onset of pathology [Neufeld and Muenzer, 2001; Clarke, 2007] . Although the MPS-I clinical phenotype represents a continuous spectrum from the severe to the attenuated forms, three distinct phenotypes have been classically distinguished: 1) severe (Hurler syndrome, MPS IH; MIM# 607014) when the onset of symptoms is before 12 months of age, with survival no more than 10 years and mental retardation manifesting before the age of three; 2) intermediate (Hurler/Scheie syndrome, MPS IH/S; MIM# 607015) when onset of symptoms is between 1 and 6 years, survival is variable and mental retardation is absent or mild, but never before 3 years of age; and 3) 'attenuated' (Scheie syndrome, MPS IS; MIM# 607016) when symptoms first become apparent after the age of 5, survival is normal and mental retardation is never present [Neufeld and Muenzer, 2001] .
The gene encoding α-L-iduronidase (IDUA; MIM# 252800) maps to chromosome 4p16.3 and contains 14 exons; the cDNA open reading frame (ORF) is ~2 kb in length and encodes a polypeptide of 653 amino acids (Scott et al., 1990 (Scott et al., , 1991 . So far, more than 100 different disease-causing IDUA mutations have been reported (Human Gene Mutation Database; http://www.hgmd.org; Stenson et al., 2009) . Several different types of mutation have been documented: whereas missense mutations may allow for some residual enzyme activity and are associated with quite a variable clinical phenotype, those mutations that are likely to impact upon RNA processing (i.e. nonsense, frameshift and splice site mutations) almost invariably result in a more severe phenotype [Terlato and Cox, 2003 ]. Non-pathogenic functional polymorphisms may also have a role in modifying the expression of IDUA mutant alleles, thereby contributing to the phenotypic and clinical heterogeneity characteristic of MPS I [Scott et al., 1995; Beesley et al, 2001; Matte et al., 2003] .
Overall, most mutations are 'private', with only four mutations (p.W402X, p.Q70X, p.P533R, p.G51D) being common in specific populations. The most common IDUA mutation is p.W402X which has a frequency of around 50% in Northern Europe, the United Kingdom, North America [Beesley et al, 2001; Clarke et al., 1994; Scott et al., 1995] and Spain ], while in Russia, Italy and Brazil its frequency has been estimated to be 4% [Voskoboeva et al., 1998 ], 11% [Gatti et al., 1997; Venturi et al., 2002] and 20% [Matte et al., 2000] , respectively . By contrast, the p.Q70X mutation is much more frequent in Scandinavia and Russia (around 50% of alleles) than in other countries Voskoboeva et al., 1998 ]. The p.P533R mutation, which probably had a North African origin, has spread to Mediterranean countries, representing 13% and 10% of IDUA mutant alleles in Italy and Spain respectively [Alif et al., 2000; Venturi et al., 2002; Voskoboeva et al., 1998 ]. Finally, the p.G51D mutation seems to be exclusively Italian with a relative frequency of 13% among IDUA mutant alleles [Venturi et al., 2002] .
We have previously reported IDUA gene mutations from a series of 30 Italian patients [Venturi et al., 2002] . Here we have characterized the underlying IDUA mutations in a group of 102 newly studied European patients, including 37 Italians, whose condition has been clinically and biochemically diagnosed as MPS I.
MATERIALS AND METHODS

Patients
The present series comprises a total of 102 European patients (pts) affected by MPS I. They are from diverse ethnic backgrounds: 37 were of Italian origin, 23 Polish, 21 Turkish, 18 Spanish, and 3 patients each from Hungary, Serbia and Greece, (Table 1 ). The diagnosis of MPS I was confirmed biochemically in all patients, demonstrating a defect of IDUA activity either in leukocytes or a fibroblast cell line. As reported in Table 1 , the clinical phenotype, defined as previously reported [Neufeld and Muenzer, 2003] , was available for all but three patients: 59% of patients presented with the severe form of the disease (MPS IH), 22% with the intermediate form (MPS IH/S) and 15% with the attenuated form (MPS IS); the remaining two patients (2%) manifested a clinical phenotype ranging between MPS IH-H/S (pt #43) and MPS IH/S-S (pt #92).
Thirty seven Italian cases and one Serbian case were recruited with the help of their attending clinicians. The remaining 64 patients from different countries were recruited and collected through a collaboration with Genzyme Corporation (Cambridge, MA, USA) as part of a pan-European project with the aim of performing the molecular characterization of all MPS I patients in Europe and collecting these data in an MPS I Registry (https://www.lsdregistry.net/mpsiregistry) [Pastores et al., 2007] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Some of the samples from the Italian patients were supplied by the "Cell line and DNA Biobank from patients affected by Genetic Diseases" in Genova (http://dppm.gaslini.org/biobank/). Following ethical guidelines, all samples obtained for analysis and storage required prior written informed consent using a form approved by the Local Ethics Committee.
Cell culture
Fibroblast cells were cultured according to standard procedures. The cell lines were cultured and maintained in RPMI medium (EuroClone, Gibco, Paisley, UK) containing 15% FCS and penicillin/streptomycin, in a humidified atmosphere containing 5% CO 2 at 37°C.
Enzymatic assay
α-L-iduronidase activity was assayed in homogenates of leukocytes and/or fibroblast cell lines using 4methylumbelliferyl-α-L-iduronide (Glycosynth, Cheshire, UK) as a substrate [Stirling et al., 1978] . Total protein was measured according to the Lowry method [Lowry et al., 1951] .
Molecular analysis
Genomic DNA was extracted from circulating lymphocytes and/or cultured fibroblasts using either the Wizard Genomic DNA Purification kit (Promega, Madison, WI) or a standard phenol-chloroform-based method.
IDUA gene exons, exon-intron boundaries and part of the 5' untranslated region were PCR amplified using specific primers designed by reference to the genomic sequence (GenBank-EMBL Accession no. NG_008103.1). Intronic primers, designed for both PCR and sequence analyses, are listed in Supp. Table S1 . PCR amplification reactions (except for exon 9) were carried out in 25µl vols containing 100ng genomic DNA, buffer 1X with 1.5mM MgCl 2 , 200µM dNTPs mix, 15pmol each primer, GC-RICH solution 1X and 0.5U proofreading PWO SuperYield DNA polymerase (Roche, Monza, Italy). Exon 9 PCR-amplification was carried out in 25µl vols containing 100ng genomic DNA, buffer 1X with 1.5mM MgCl 2 , 200µM dNTPs mix, 15pmol each primer and 0.5U GoTaq DNA polymerase (Promega, Madison, WI); owing to the use of a no-proofreading DNA polymerase, this reaction was performed in duplicate. Cycling conditions were: initial denaturation at 96°C for 5 min, 28 cycles denaturation at 96°C for 1 min, annealing at 63-70°C for 1 min, extension at 72°C for 1 min, followed by final extension at 72°C for 7 min. Control PCR reactions, in which no template was added, were included during each set of PCR reactions. PCR products were controlled for contamination by gel electrophoresis and were then purified using an enzymatic reaction containing 5U exonuclease I (Celbio, Italy) and 1U alkaline phosphatase (Promega, Madison, WI) under the following conditions: 15 min at 37°C followed by 15 min at 80°C.
Total RNA was prepared from peripheral blood lymphocytes isolated by the Fycoll method or from cultured fibroblasts using Trizol Reagent (Gibco, Paisley, UK) according to the manufacturer's instructions. First-strand cDNAs were synthesized using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and random hexamer primers. IDUA exonic fragments flanking splicing mutations were amplified and sequenced using primers and conditions listed in Supp. Table S1 .
Sequence analysis of PCR and RT-PCR products was performed in the forward and reverse directions using BigDye v3.1 terminator technology (Applied Biosystems, Foster City, CA) and then purified with Wizard MagneSil Sequencing Reaction Clean-Up System (Promega, Madison, WI). Sequencing reactions were carried out, the products purified according to the manufacturer's instructions and analyzed on an ABI Prism 3130 Avant Automatic Sequencer (Applied Biosystems, Foster City, CA). Sequence alterations were confirmed by sequencing duplicate PCR products.
The question of the pathological authenticity of the novel IDUA sequence alterations detected was addressed by (i) searching dbSNP (http://www.ncbi.nlm.nih.gov/SNP) for their presence, (ii) screening 100 alleles from healthy control subjects for each alteration, (iii) modeling the amino acid changes into a homologous three-dimensional structure of the protein, (iv) employing the MutPred program [Li et al., 2009; Mort et al., 2010] for the missense mutations, (v) using ESRPred and a neural network for splice site prediction [Krawczak et al., 2007] for the coding region variants upon splicing, and (vi) using PhyloP method [Pollard et al., 2010] and ClustalW2 program [Larkin et al., 2007] to measure evolutionary conservation of nucleotides and residues, respectively. 
Molecular modeling of missense mutations
For modeling of the IDUA missense mutations, an homology model of the IDUA protein was used. This model was built by Rempel et al. (2005) using the atomic coordinates of β-xylosidase (E.C.3.2.1.37) from Thermoanaerobacterium saccharolyticum as a template [PDB code 1Y24]. Visual inspection and graphical representations were then performed using the programs Coot and Chimera, respectively [Emsley and Cowtan, 2004; Pettersen et al., 2004] .
Bioinformatic analysis of IDUA variants
Missense variants in the IDUA gene were analysed with a computational model, MutPred [Li et al., 2009 , Mort et al., 2010 . MutPred is designed to assess the likely phenotypic consequences of missense substitutions occurring within sites of structural and/or functional importance, on the wild-type protein sequence. MutPred can be used to generate hypotheses as to the underlying molecular mechanism(s) responsible for disease pathogenesis.
The effect of the coding region variants upon splicing [splice site disruption, cryptic splice site activation and exon skipping via loss of exonic splicing enhancers (ESE) and/or gain of exonic splicing silencers (ESS)] was ascertained using ESRPred [M. Mort, unpuplished] and a neural network for splice site prediction [Krawczak et al., 2007] .
Evolutionary sequence conservation across an alignment of IDUA orthologues from 44 vertebrate species was measured using the phyloP method [Pollard et al., 2010] . PhyloP can measure accelerated evolution (more rapid evolution than expected under neutral drift) as well as evolutionary conservation (slower than expected evolution). A positive phyloP score represents an evolutionarily conserved nucleotide and a negative phyloP score indicates that the nucleotide has experienced more rapid evolution than would be expected under neutral drift.
Mutation nomenclature
Mutations
are described according to current mutation nomenclature guidelines (http://www.hgvs.org/mutnomen), ascribing the A of the first ATG translational initiation codon as nucleotide +1 [den Dunnen and Antonarakis, 2000; den Dunnen and Paalman, 2003] .
RESULTS AND DISCUSSION
A total of 102 European patients affected by MPS I were recruited by our centre. All patients underwent molecular characterization and the IDUA genotype was completely ascertained in 93 of the 102 patients.
Mutation detection
All 14 exons, splice junctions and proximal portions of the 5' and 3' untranslated regions of the IDUA genes of the 102 unrelated MPS I patients were investigated by DNA sequence analysis. Putatively pathological IDUA mutations were identified in 193 of 204 alleles. The genotypes, clinical phenotypes and geographic origins of the 102 patients studied here are listed in Table 1 . The characteristics of the 55 distinct IDUA mutations identified are reported in Table 2 . The mutational spectrum comprised 22 missense mutations, 14 splice site alterations, 9 microdeletions, 5 nonsense mutations, 3 micro-duplications, 1 translational initiation site mutation and 1 no-stop mutation. More than 60% (35/55) of these mutant alleles have not been previously reported, attesting to the extensive allelic heterogeneity of MPS I. The novel lesions resulted from (i) 11 missense mutations (p.Y76C, p.G84R, p.T103P, p.G219E, p.E276K, p.W306L, p.N384K, p.P385R, p.L396P, p.A436P, p.L535F) as well as two missense mutations located in cis to each other (p. 
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Human Mutation
Missense mutations
A total of 14 novel IDUA missense mutations were detected during the course of this study; two being located in cis on the same IDUA allele (p.[F188L;S423R]). Consistent with their putative pathological authenticity, none of the underlying nucleotide changes were found in a screen of 100 control alleles. Nor were any of these substitutions listed as polymorphisms in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP).
Bioinformatic analysis of missense variants
MutPred predicted that most of the missense mutations listed in Table 2 are deleterious (91%; 21 out of 23; MutPred general score > 50). Further, confident in silico hypotheses for the underlying mechanism of pathogenesis were generated for 14 of the missense mutations (summarised in Table 2 and reported in full in Supp. Table S3 ). The two missense mutations (p.T103P and p.A436P) predicted not to be deleterious by MutPred, were analysed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 . Table S4 ). PhyloP scores were used to measure evolutionary conservation at the nucleotide sequence level across IDUA orthologues derived from 44 vertebrate species. Both mutations (p.T103P and p.A436P) exhibited positive phyloP scores indicating that these mutations are located at conserved nucleotides. It should be noted that p.T103P displays only marginal conservation, with a phyloP score of 0.40. Analysis with SIFT [Ng and Henikoff, 2001] predicted that both mutations would be tolerated in the protein. PolyPhen2 [Adzhubei et al., 2010] however predicted that whilst p.T103P was benign, p.A436P mutation was likely to be potentially damaging. Neither mutation was predicted to disrupt splicing using a neural network [Krawczak et al., 2007] . MutPred analysis was also performed on the six polymorphic missense variants identified (listed in Supp. Table S2 ) but none of these were predicted to be deleterious (MutPred general scores invariably < 50).
Further evidence for the pathological/functional significance of the missense mutations was then sought from the analysis of the extent of evolutionary conservation of the mutated residues in 6 orthologous (vertebrate) IDUA proteins from human to Tetraodon nigroviridis. The computational analysis, carried out using ClustalW2 [http://www.ebi.ac.uk/clustalw; Larkin et al., 2007] , revealed that among the 5 other vertebrate IDUA protein sequences examined, Y76, G84, F188, G219, R276, W306, N348, P385, L396, S423, L535 were invariant at these positions; such conservation over 500 Myrs of evolutionary time is supportive of the functional significance of these residues and hence the direct involvement of the respective mutations in disease causation. In agreement with the PolyPhen score results, residue A436 was found to be partially conserved (chimpanzee, dog and chicken) but T103 was not evolutionarily conserved. (Supp. Figure S1 ). It may be that the p.A436P mutation is mildly deleterious, whereas p.T103P may be tolerated and could therefore represent a rare polymorphism.
3D modelling of IDUA missense mutations
To shed further light on the deleterious consequences of the novel missense IDUA mutations at the protein level, we employed the homology model of IDUA constructed by Rempel et al. [2005] . Since the IDUA model starts at residue 36 and terminates at residue 522, the p.L535F substitution could not be included in this analysis. As shown in Figure 2 , and detailed in Supp. Table S5 , several substitutions (p.G219E, p.P385R and p.S423R) appear to affect a hydrophobic buried region in the protein, one substitution occurs in the predicted active site residue (p.F188L), and one substitution in the active site cleft (p.W306L) [Rempel et al., 2005] . The remaining amino acid replacements (p.G84R, p.Y76C, p.T103P, p.E276K, p.N348K, p.L396P and p.A436P) affected solvent accessible residues. Consistent with previous findings [Rempel et al., 2005; Vazna et al., 2009; Sugawara et al., 2008] , those mutations that occur in the protein core (including the predicted active site), were associated with the severe (H) form of MPS I, whereas the missense mutations which affected surface-located residues were associated with the more attenuated clinical phenotypes (H/S, S) ( Figure 2 and Supp. Table  S5 ). Despite obtaining data from both structural and bioinformatic analyses, the pathological significance of the p.T103P, which occurs in a long loop of unknown function that protrudes into the solvent, remains unclear. Exon 12 Exon 13
Splicing mutations
A substantial proportion of the novel IDUA mutations detected (34.3%) occurred in either the donor (c.385+1G>A, c.493+1G>A, c.1727+1G>A) or acceptor (c.494-1G>A, c.1190-1delG) splice sites or in the surrounding splicing motifs (c.1189+4A>G, c.1189+5G>A, c.1650+5G>C, c.1727+4C>T, c.1727+5G>C, c.1727+6T>A) ( Table 2) . All the single base-pair substitutions predicted to disrupt splicing were located at nucleotides which were evolutionarily conserved across an alignment of IDUA gene sequences from 44 vertebrate species. We also identified an indel mutation (c.956_972+9delinsTA) as the cause of aberrant splicing in one case. At the genomic level, the mutation comprised the deletion of 26 nucleotides and the insertion of the dinucleotide TA in a region overlapping the exon-intron 7 donor splice site.
Supp. Figure S2 graphically represents the intronic location of the 12 novel splicing mutations identified in MPS I patients in the present study. To assess the potential effect of these mutations on mRNA splicing, the relative strengths of the 5' and 3' splice site signals were evaluated using the NetGene2 server [http://www.cbs.dtu.dk/services/NetGene2]. According to this program, all 12 mutations would be predicted to impact upon RNA processing. In particular, donor splice sites would have been abrogated in the presence of c.385+1G>A, c.493+1G>A, c.1650+5G>C, c.1727+1G>A, c.1727+5G>C and c.1727+6T>A as would acceptor sites in the presence of c.494-1G>A and c.1190-1delG. The same analysis predicted a considerable decrease in the donor splice site confidence score in the cases of c.1189+4A>G, c.1189+5G>A and c.1727+4C>T.
These predictions were then followed up by performing in vitro splicing analysis for those mutations identified in patients from whom appropriate samples were available. The functional relevance of six intronic mutations (c.494-1G>A, c.1189+4A>G, c.1189+5G>A, c.1727+4C>T, c.1727+5G>C and c.1727+6T>A) was assessed by carrying out reverse transcriptase-polymerase chain reaction (RT-PCR) analysis on mRNA extracted from either lymphocytes (3 pts) or fibroblast cell lines (3 pts). In the case of c.1727+5G>C and c.1727+6T>A, the RT-PCR results clearly confirmed the abrogation of the expected donor splice site leading to the skipping of exon 12 or the activation of alternative splice sites (exonic or intronic) leading to frameshifts with consequent premature truncation of the protein (p.Y167TfsX, p.V371MfsX, p.L578VfsX). Full details are given in Table 3 . Genotypes, clinical phenotypes and geographic origins of the 102 patients studied here are listed in Table 1 . Some 45 (44%) of the patients (pts) were found to be either homozygous for the pan-ethnic IDUA mutations, p.W402X (12 pts), p.Q70X (9 pts) and p.P533R (3 pts), other known mutations (7 pts) or novel lesions (14 pts).
The remaining 54% of patients were compound heterozygotes (including 7 in whom the second mutant IDUA allele could not be identified). Finally, the mutant IDUA alleles in two patients (2%), in whom a defect in IDUA enzyme activity had been documented, remained unidentified.
Overall, we found 68 distinct genotypes including those (7) that were partially characterized. Our results confirm the high degree of mutational heterogeneity characteristic of MPS I. Extensive allelic heterogeneity often precludes the recognition of correlations between mutant genotypes and variant clinical phenotypes. This notwithstanding, in an attempt to obtain new insights into the genotype-phenotype relationship in MPS I, we have compared the genotypes present in our patient series with those of previously reported patients. Supp. Table S6 , reports the comparable genotypes (13/68) and the respective number of patients per genotype reported in previous studies on this topic.
Among the analyzed group, 25 patients were either homozygous or compound heterozygous for the two common deleterious nonsense mutations (p.Q70X and p.W402X); their severe clinical phenotype concurred with those of 91 previously reported patients with comparable genotypes Gort et al., 1998; Hein et al., 2003; Li et al., 2002; Matte et al., 2003; Vazna et al., 2009; Venturi et al., 2002; Voskoboeva et al. 1998 ]. In agreement with previously reported genotype-phenotype correlations, a severe phenotype was not only associated with the p.W402X mutation in compound heterozygosity with both c.1650+5G>A and p.A327P Venturi et al., 2002; Vazna et al., 2009] but also with homozygosity for p.A327P and p.G51D [Gatti et al., 1997] . Also consistent with previous data [Beesley et al, 2001; Tieu et al., 1995 ] , homozygosity for p.L490P and compound heterozygosity for p.Q70X and c.1333_1335del3 yielded mild phenotypes in two other patients (Supp . Table S6 ). Although for these 38 patients (37%), the predicted genotype-phenotype relationship may be considered informative, for the remaining group with previously described genotypes, the correlations only partially concurred (Supp . Table S6 ). This latter group comprised 6 patients, 3 of whom were homozygous either for the p.P533R mutation or for the microdeletion c.46_57del12 (2 pts), and another patient who was compound heterozygous for p.G51D and p.P533R. Comparison between the genotype-phenotype correlation data from our 6 patients and 23 patients from other studies [Alif et al., 1999; Hein et al., 2003; Gatti et al., 1997; Hein et al., 2003 , Laradi et al., 2005 Matte et al., 2003; Venturi et al., 2002] confirmed the phenotypic variability of these mutations (p.P533R and c.46_57del12). Similarly, in our patient series (Table 1) , these two latter mutations (p.P533R and c.46_57del12), although present in both the homozygous or compound heterozygous state, and in a significant number of individuals (viz. pts #5, #8, #37, #72, #80 and pts #24, #27, #45, #48, #84, #94, respectively), were found to be associated with a wide range of clinical severity.
Additional conclusions were drawn by individually comparing some mutations in our series (Table 1) with those from previous studies. According to Hein et al. [2003] , mildly deleterious consequences could be confirmed for the mutation p.R89W, contributing to the mild form of MPS I noted in pts #7 and #13, in whom this allele was in association with the already known severe mutations, p.G51D and p.P496R, respectively. In our own patients, this latter allele (p.P496R) was invariably found to be associated with the severe form of MPS I (pts #6, #17, #19, #22, #23, #30, #33); this finding confirms the assessment of its detrimental nature, made in vitro, by Beesley et al. [2001] . The only patient harbouring p.P496R to exhibit an intermediate clinical form of MPS I (pt #1) was a compound heterozygote in whom the clinical effect of this detrimental allele was probably attenuated by the relative benign influence of p.G265R. In support of this latter supposition was the compound heterozygosity (p.G265R+p.Q70X) observed in the Scheie patient #44 (Table 1) . Conversely, conclusions as to the genotypephenotype relationship manifested by mutation c.494-1G>A, found in either the homozygous (pts #81, #86, #90, #98) or compound heterozygous (pt #92) state, were equivocal since this lesion was associated with very different degrees of clinical severity, even in patients who appeared to share the same genetic background (Table 1 ). It may be that other genetic or non-genetic factors can modulate the clinical phenotype in MPS I. Among the possible genetic factors involved, as previously reported in the same MPS I [Yogalingam et al., 2004] or in other MPSs such as MPS II [Lualdi et al., 2006] , are differentially spliced-RNA transcripts that might result from the splicing mutation c.494-1G>A, and could potentially be considered as modifiers of the clinical phenotype [Nissim-Rafinia and Kerem, 2002] . Unfortunately, RNA samples were not available to permit experimental verification.
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Human Mutation
Frequency and geographical distribution of common and rare mutations in the European polulation As reported in Table 2 , in the whole series comprising patients with diverse genetic backgrounds, the frequency of the most common mutations was: p.Q70X (18.6%), p.W402X (18%), p.G51D (4.9%), p.P496R (4.4%) p.P533R (3.9%), p.A327P (2.4%) and c.46_57del12 (3.9%). Altogether, they represented 56% of IDUA alleles. Rare or private mutations comprised 49.5% of IDUA lesions, and 28.4.% of these were novel. However, when we analysed the geographical distribution and relative frequencies of the five most frequent mutations in different areas of Europe, we observed significant differences in the distribution of these mutations (Figure 3) . In Western Europe, the most frequent mutation was p.W402X, representing 38.8% of alleles in Spain. Although its relative frequency in the other Mediterranean countries decreased sharply to 9.5% in both Italy and Turkey, p.W402X maintained a relatively high frequency in Northern Europe, accounting for 24% of IDUA alleles in our series of patients from Poland. Conversely, the p.Q70X mutation accounted for 39% of IDUA alleles in Poland but progressively decreased in terms of its frequency in a Southerly direction, constituting 14.9% in Italy, 8.3% in Spain and 7.1% in Turkey. On the basis of these results, and supported by previous data [Terlato and Cox, 2003] , it could be speculated that the European geographical diffusion of p.W402X occurred from the South-West in a Northerly direction, while that of p.Q70X occurred from the North-East in a Southerly direction. Mediterranean countries appear to have balanced the relatively low frequency of these two common mutations with other 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w mutations specific to this geographical region viz. p.P533R, p.P496R and p.G51D, the latter two being specific to (and recurrent in) the Italian population, and c.494-1G>A, a Turkish-specific mutation (not shown in the figure). The relatively low frequency of the two usually common mutations (p.Q70X and p.W402X) in Italy and Turkey, results in an increase in IDUA allelic heterogeneity in these two countries as compared to Northern European countries. Thus, rare mutations accounted for 50% and 71.4% of alleles in Italy and Turkey, respectively, as compared to Poland and Spain where they were 37% and 41.6% respectively. The finding that European countries vary widely in terms of both the distribution and frequency of IDUA gene mutations has important implications for the selection of screening strategies in individual countries. The existence of dramatic differences in mutational heterogeneity and mutation prevalence highlights the importance of multi-national screening studies in helping to elucidate the genotype-phenotype relationship in disorders such as MPS I that are characterized by extensive allelic heterogeneity. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure S1 . Evolutionary comparison of the protein sequences flanking the missense mutations identified in the human IDUA protein with their orthologous counterparts in 5 vertebrates (in silico data from http://www.ebi.ac.uk/clustalw/). From the top: From the top: Homo sapiens, Pan troglodytes, Canis familiaris, Mus musculus, Gallus gallus, Tetraodon nigrovisidis. Positions of mutations are marked by vertical boxes. Note that the translational initiation site substitution, predicted to produce either no protein or to move the initiation site up/downstream (p.M1?), was excluded from the analysis.
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